LED Medical Diagnostics, Inc. Retains MZ Group as Investor Relations Advisor
"We are pleased to be partnering with MZ Group to expand our investor relations efforts," said Dr. David Gane, CEO of LED Medical. "We continue to execute on our business plan and have enhanced shareholder value in a number of ways. The time is right for the Company to expand awareness, and MZ Group has an excellent track record assisting emerging growth companies in this endeavor. MZ offers a platform which includes direct introductions with retail and institutional investors, virtual conferences, non-deal road shows, access to key conferences and many other services designed to reach new prospective investors, and we are excited to get started."
Ted Haberfield, President of MZ Group North America stated, "LED Medical is at the right place at the right time to grow its dental imaging segment as dentists migrate from analog to digital and 2D to 3D. The Company has positioned itself as a leading player in the North American digital imaging technology market as the developer of the VELscope®Vx for early detection of oral mucosal diseases (including cancer/pre-cancer). The global market for dental imaging systems is predicted to reach over $2.3B by 2022 and LED Medical is expanding quickly to capture market share. We look forward to helping the Company with all aspects of its corporate communications and investor relations needs."
Under the agreement, the Company will pay US$7,000 per month to MZ Group and will grant 350,000 stock options at an exercise price of US$0.25 which will vest quarterly over one year. The initial term of the agreement is 6 months with a provision for automatic 12-month renewals. If the first renewal term is exercised, the Company has agreed to grant a further 150,000 stock options at an exercise price to be determined with vesting and pricing to be in accordance with TSX Venture Exchange requirements. MZ Group is based in Carlsbad, California, and does not presently own any securities of the Company. The agreement to retain MZ Group is subject to TSX Venture Exchange approval.About LED Medical Diagnostics, Inc.
Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiary LED Dental, provides dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.The Company is currently listed on the TSX Venture Exchange (TSX-V) under the symbol LMD, the OTCQX under the symbol LEDIF, as well as the Frankfurt Stock Exchange under the symbol LME. For more information, call 844.952.7327 or visit www.leddental.com/investor-relations. About MZ Group
MZ, founded in 1999, combines capital markets intelligence, global investor targeting, IR technology, corporate governance, media and corporate communication and IR consulting, providing comprehensive programs that successfully build and manage shareholder value. With a team of highly experienced senior professionals and an integrated service portfolio, MZ ensures that companies are provided with the right tools and strategies to interact effectively with the investment community and the media, successfully conveying the investment message. MZs market intelligence, advisory and tactical support activities for investor relations and corporate communications programs are underpinned by a comprehensive IT infrastructure, allowing companies to rapidly achieve global standards of best practices. For more information, please visit www.mzgroup.us.
Dr. David Gane
Chief Executive Officer
For Investor Relations, please contact:
MZ North America
Vice President Â North America
Forward Looking Statement
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future growth strategy, its distribution strategy and product offerings, potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2013. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.